Eton Pharmaceuticals has successfully in-licensed the US commercialization rights for Hemangeol® (propranolol hydrochloride) oral solution from Pierre Fabre Medicament Sas.1 This strategic move marks a significant milestone for the Illinois-based company, as Hemangeol becomes the tenth commercial product in its expanding rare disease portfolio.